Vise Technologies Inc. Purchases New Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Vise Technologies Inc. purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,085 shares of the company's stock, valued at approximately $319,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. McIlrath & Eck LLC boosted its stake in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Prestige Consumer Healthcare by 24.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company's stock worth $9,223,000 after purchasing an additional 23,334 shares during the period. Vident Advisory LLC boosted its stake in Prestige Consumer Healthcare by 2.8% in the 4th quarter. Vident Advisory LLC now owns 11,254 shares of the company's stock worth $879,000 after purchasing an additional 305 shares during the period. ProShare Advisors LLC boosted its stake in Prestige Consumer Healthcare by 44.4% in the 4th quarter. ProShare Advisors LLC now owns 14,925 shares of the company's stock worth $1,165,000 after purchasing an additional 4,590 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in Prestige Consumer Healthcare by 8.9% in the 4th quarter. Quantinno Capital Management LP now owns 9,013 shares of the company's stock worth $704,000 after purchasing an additional 739 shares during the period. Institutional investors own 99.95% of the company's stock.

Analysts Set New Price Targets

PBH has been the subject of several analyst reports. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. DA Davidson raised their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Trading Up 1.5%

Prestige Consumer Healthcare stock traded up $1.30 during trading hours on Friday, reaching $85.78. The company had a trading volume of 330,734 shares, compared to its average volume of 298,487. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The company has a 50-day moving average price of $83.58 and a 200 day moving average price of $82.39. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of 20.09, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $1.02 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.